Pages that link to "Q35754532"
Jump to navigation
Jump to search
The following pages link to Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma (Q35754532):
Displaying 50 items.
- Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis (Q26765151) (← links)
- Advanced and relapsed/refractory Hodgkin lymphoma: what has been achieved during the last 50 years (Q26829198) (← links)
- Phase II study of sorafenib in patients with relapsed or refractory lymphoma. (Q33401136) (← links)
- Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma (Q33404875) (← links)
- Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers (Q33420273) (← links)
- Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies (Q33886267) (← links)
- Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma (Q34064220) (← links)
- The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients (Q34240314) (← links)
- Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin's lymphoma (Q35705317) (← links)
- Late Relapses following High-Dose Autologous Stem Cell Transplantation (HD-ASCT) for Hodgkin’s Lymphoma (HL) in the ABVD Therapeutic Era (Q35717972) (← links)
- A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma (Q35925674) (← links)
- Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients (Q36371623) (← links)
- Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience (Q37126593) (← links)
- Impact of disease status and stem cell source on the results of reduced intensity conditioning transplant for Hodgkin's lymphoma: a retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). (Q37144910) (← links)
- Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis (Q37388718) (← links)
- Simplified validated prognostic model for progression-free survival after autologous transplantation for hodgkin lymphoma (Q37530611) (← links)
- Treatment pathways and resource use associated with recurrent Hodgkin lymphoma after autologous stem cell transplantation. (Q37683355) (← links)
- Emerging drugs for Hodgkin's lymphoma (Q37772513) (← links)
- Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate (Q38073207) (← links)
- Brentuximab vedotin: an anti-CD30 antibody-drug conjugate (Q38091629) (← links)
- Management of relapsed or refractory hodgkin lymphoma with second-generation antibody-drug conjugates: focus on brentuximab vedotin. (Q38164572) (← links)
- Current status of prognostication in classical Hodgkin lymphoma (Q38185063) (← links)
- Recurrent Hodgkin lymphoma: toward a new definition of candidates for autologous stem cell transplant in the era of positron emission tomography scan and novel agents. (Q38264356) (← links)
- Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory hodgkin lymphoma. (Q38368587) (← links)
- Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. (Q38386440) (← links)
- Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment. (Q38466376) (← links)
- Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma (Q38557033) (← links)
- Pretransplant functional imaging and outcome in pediatric patients with relapsed/refractory Hodgkin lymphoma undergoing autologous transplantation (Q38684561) (← links)
- Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis (Q38781590) (← links)
- Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland (Q38912382) (← links)
- Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience (Q38951604) (← links)
- Improving outcomes after allogeneic hematopoietic cell transplantation for Hodgkin lymphoma in the brentuximab vedotin era (Q38992200) (← links)
- BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts. (Q39021652) (← links)
- Accelerated Total Lymphoid Irradiation-containing Salvage Regimen for Patients With Refractory and Relapsed Hodgkin Lymphoma: 20 Years of Experience. (Q39195424) (← links)
- Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts (Q39202496) (← links)
- Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma? (Q39294879) (← links)
- Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation (Q40149586) (← links)
- Treatment strategy based on gemcitabine-containing salvage chemotherapy used with intent to proceed to second stem cell transplant for patients with Hodgkin lymphoma relapsing after a prior autologous transplant (Q44120728) (← links)
- 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma (Q44750052) (← links)
- Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin (Q46698290) (← links)
- Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma (Q47130656) (← links)
- Interesting activity of pegylated liposomal doxorubicin in primary refractory and multirelapsed Hodgkin lymphoma patients: bridge to transplant. (Q48178853) (← links)
- Transplant strategies in relapsed/refractory Hodgkin lymphoma. (Q52676516) (← links)
- Bendamustine as a bridge to allogeneic transplant in relapsed/refractory Hodgkin lymphoma patients who failed salvage brentuximab vedotin postautologous peripheral blood stem cell transplantation. (Q52779365) (← links)
- PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. (Q53026185) (← links)
- Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial (Q56383260) (← links)
- Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma (Q57028105) (← links)
- Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party (Q57796234) (← links)
- Prognostic Factors (Q62096508) (← links)
- Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-H (Q88098107) (← links)